bioRxiv · 10.1101/2023.04.17.537235
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity
Abstract
An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 ({triangleup}3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of {triangleup}3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the {triangleup}3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest {triangleup}3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Adam, A., Kalveram, B., Chen, J. Y.-C., Yeung, J., Rodriguez, L., Singh, A., Shi, P.-Y., Xie, X., Wang, T.. 2023-04-18. A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity. https://doi.org/10.1101/2023.04.17.537235
Cite the original work for its findings. Save a collection to share your selection of sources.